ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Loading news article.

ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma | WAPE

ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Article summary

Related companies

Analyzed by WAPE AI.

Comments —